Cargando…
Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit
Palivizumab is currently licensed for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children with chronic lung disease, with a history of preterm birth, or with haemodynamically significant congenital heart disease, but its routine use during outb...
Autores principales: | Dizdar, E.A., Aydemir, C., Erdeve, O., Sari, F.N., Oguz, S., Uras, N., Dilmen, U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Hospital Infection Society. Published by Elsevier Ltd.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132464/ https://www.ncbi.nlm.nih.gov/pubmed/20299133 http://dx.doi.org/10.1016/j.jhin.2010.01.013 |
Ejemplares similares
-
Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab Prophylaxis
por: Oncel, Mehmet Yekta, et al.
Publicado: (2013) -
Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit
por: Alan, S., et al.
Publicado: (2012) -
Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study
por: Terletskaia-Ladwig, Elena, et al.
Publicado: (2005) -
Hydrops Fetalis due to Kell Alloimmunization: A Perinatal Approach to a Rare Case
por: Akdağ, Arzu, et al.
Publicado: (2012) -
A Neonate with Subcutaneous Fat Necrosis after Passive Cooling: Does Polycythemia Have an Effect?
por: Calisici, Erhan, et al.
Publicado: (2013)